Prix Duality Biotherapeutics Inc (09606.HK)

Duality Biotherapeutics, Inc. operates as a clinical stage company. The company is headquartered in Shanghai, Shanghai and currently employs 191 full-time employees. The company went IPO on 2025-04-15. The firm is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The firm's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The firm's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The firm principally conducts its businesses in domestic and overseas markets.